Synergistic Combinations for Lowe Syndrome Treatment

The inventive concept integrates RhoA inhibitors, statins, and mTOR inhibitors with distinct technologies like AI, IoT, blockchain, and new materials to create a more powerful system for treating Lowe Syndrome.

Lowe Syndrome is a devastating genetic disease with limited treatment options. The original patent disclosed RhoA inhibitors, statins, and mTOR inhibitors as therapeutic agents, but their individual efficacy is limited. The new inventive concept addresses this limitation by combining these agents with other technologies to create a more effective treatment system.

The inventive concept comprises various synergistic combinations, including a system with a RhoA inhibitor, a statin, a mTOR inhibitor, and an artificial intelligence module for monitoring and optimizing treatment outcomes. Another embodiment involves a blockchain-based platform for storing and analyzing patient data, in combination with the therapeutic agents. Additionally, the inventive concept encompasses a pharmaceutical composition with a nanomaterial-based delivery system and a system for monitoring and predicting treatment outcomes using a machine learning algorithm and an IoT-enabled device. These combinations leverage the strengths of each technology to create a more powerful treatment system.

The new claims introduce novel combinations of RhoA inhibitors, statins, and mTOR inhibitors with AI, IoT, blockchain, and new materials, which are not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more effective treatment system for Lowe Syndrome.

Alternative embodiments of the inventive concept could include using different AI algorithms, varying the type of nanomaterial used in the delivery system, or incorporating additional technologies like 3D printing or robotics. These variations ensure broad conceptual coverage and adaptability to future advancements in the field.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of rare genetic diseases like Lowe Syndrome. The market for such treatments is expected to grow, driven by increasing demand for personalized and effective therapies.